eom-pharmaceuticals PRESS RELEASE ARCHIVE

Dec 2, 2021

EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

Aug 24, 2021

EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil España - español Deutschland - English Brazil - Português France - Français Italia - Italiano Deutschland - Deutsch USA - English

Jul 22, 2021

EOM Pharmaceuticals Appoints Drug Development Veteran Frank L. Douglas, Ph.D., M.D., Scientific Advisor

Dec 23, 2020

EOM Pharmaceuticals Announces Its Pre-IND Meeting Request With U.S. FDA to Evaluate Plans for a Phase 2 Clinical Trial of Its Investigational Dual-Acting, Broad-Spectrum Immunomodulator in COVID-19 Patients

Google Analytics Alternative